GRAL · GRAIL, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on GRAL. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About GRAL · GRAIL, Inc.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Live Quote
SELL (score -3) · 12-1 mom 54.4% · RSI 49.5 · above_50_only · -47.3% from high
Targets blend Wall Street consensus (8 analysts: low $56.00 / mean $66.00 / high $80.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Stage produced output that could not be parsed as a valid JSON object. ~6h cooldown before retry.
{"symbol":"GRAL","company":"GRAIL, Inc.","investigation_summary":"GRAIL is a commercial-stage healthcare company whose Galleri multi-cancer early detection test has strong revenue growth (37% YoY in Q1 2026 to $39.8M screening revenue) and improving operational metrics but remains pre-profitability with significant binary catalysts. The investigation trigger was four recent Form 4 filings, all of